GKOS (Glaukos) Valuation Rank


GKOS Glaukos Corp GKOS
81 GF Score
Price $137.76
GF Value $135.34
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Glaukos Valuation Rank Related Terms

GKOS
81GF Score
Glaukos Corp GKOS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $137.76 is trading 1.8% above its estimated GF Value™ of $135.34. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Valuation Rank:
  • GF Value™: $135.34 vs. price of $137.76 (1.8% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
81GF Score

Get the complete analysis for GKOS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$137.76
Price
$135.34
GF Value